Cancer as one of the most prevalent health issues accounts for 13 percent of all deaths worldwide. Based on a report by the American Cancer Society, breast, colorectal, and prostate cancers will be the three leading causes of death among Americans in 2018. The development of sequence-specific RNA molecules that may effectively knock out selected gene expression provides the chance of rational design for targeted cancer therapies. Stathmin 1/oncoprotein 18 may be a major regulator of microtubule dynamics. Stathmin1 is extremely overexpressed in a vast array of human malignancies, such as breast, colorectal, and prostate cancers. This study compares the effects of viable Stathmin1 knockdown, migration, and proliferation of pc3, mcf7 and sw480 cancer cell lines from breast, colorectal, and prostate cancer cells. Our result showed that response of the prostate cancer cell line to suppression of STMN1by siRNA is more considerable compared to that of breast and colorectal cancers’ cell lines. Considering the importance of issue under study, further investigations are recommended to be done on STMN1 siRNA as a pharmacological intervention strategy in prostate cancer.
